BACKGROUND

Hidradenitis suppurativa (HS) is a chronic recurrent disease. The high cost of HS and its complications treatment, long periods of temporary disability and the development of incapacity force to find ways of the quality of patients’ life improvement and the socio-economic burden reduction.

OBJECTIVE

Assessment of the economic burden and economic prospects of genetically engineered biological drugs (GEBD) provision to HS patients in the Russian Federation.

MATERIAL AND METHODS

An analysis of the HS prevalence on the basis of data from epidemiological studies, statistical indicators of the Ministry of Health of the Russian Federation and assessments of specialized professionals was carried out. A mathematical variable-based model for the calculation of HS economic burden in the Russian Federation has been developed. It allows to determine direct and indirect financial costs associated with the treatment of the main disease and its complications, loss from temporary and persistent disability, development of incapacity.

RESULTS

The economic burden without the use of GEBD on one HS patient was almost 300 thousand. rub., on the population of HS patients — 43.9 billion rub. Provision of GEBD to only 5% of the most severely ill HS patients will reduce the duration of temporary disability by 65%, the level of incapacity by 90%, and reduce the annual economic burden from 43.9 billion to 29.0 billion rub. Substantial saving of budget funds is expected from the third year of GEBD implementation, thus the quality of patients’ life is improved after the first 12 weeks of therapy and significantly higher during the first year.

CONCLUSION

The provision of HS patients with GEBD is a promising direction for improving the health care delivery and is economically feasible. Adjustments in a number of laws and regulations are necessary in order to provide GEBD accessibility.